http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Bohyun,Park, Seong Ho,Hong, Gil-Sun,Lee, Ju Hee,Lee, Jong Seok,Kim, Hyun Jin,Kim, Ah Young,Ha, Hyun Kwon Springer International 2015 European radiology Vol.25 No.6
<P>We aimed to compare iohexol vs. diatrizoate as fecal/fluid tagging agents for computed tomography colonography (CTC) regarding examination quality.</P>
Monodisperse Microshell Structured Gelatin Microparticles for Temporary Chemoembolization
Kim, Bohyun,Han, Sang Woo,Choi, Song-Ee,Yim, DaBin,Kim, Jong-Ho,Wyss, Hans M.,Kim, Jin Woong American Chemical Society 2018 Biomacromolecules Vol.19 No.2
<P>Embolization is a nonsurgical, minimally invasive procedure that deliberately blocks a blood vessel. Although several embolic particles have been commercialized, their much wider applications have been hampered owing mainly to particle size variation and uncontrollable degradation kinetics. Herein we introduce a microfluidic approach to fabricate highly monodisperse gelatin microparticles (GMPs) with a microshell structure. For this purpose, we fabricate uniform gelatin emulsion precursors using a microfluidic technique and consecutively cross-link them by inbound diffusion of glutaraldehyde from the oil continuous phase to the suspending gelatin precursor droplets. A model micromechanic study, carried out in an artificial blood vessel, demonstrates that the extraordinary degradation kinetics of the GMPs, which stems from the microshell structure, enables controlled rupturing while exhibiting drug release under temporary chemoembolic conditions</P>
( Bohyun Kim ),( Soon Sun Kim ),( Sung Won Cho ),( Jae Youn Cheong ),( Jimi Huh ),( Jai Keun Kim ),( Jei Hee Lee ),( Hye Ri Ahn ),( Hyo Jung Cho ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Liver stiffness (LS) is an emerging imaging-based prognostic biomarker for patients with chronic liver disease. We investigated whether LS quantified using magnetic resonance elastography (MRE) could predict the prognosis of advanced hepatocellular carcinoma (HCC) patients treated with sorafenib. Methods: We selected 50 sorafenib-treated advanced HCC patients who underwent MRE within 3 months before drug administration from a prospectively maintained cohort of chronic liver disease patients, according to the inclusion and exclusion criteria. Univariate and multivariate analyses were performed to evaluate the prognostic role of laboratory data, tumor characteristics, and MRE-assessed LS for overall survival (OS), progression-free survival (PFS), and significant liver injury (≥grade 3) after sorafenib administration. Results: High MRE-assessed LS was significantly associated with poor OS (kPa; hazard ratio [HR], 1.54; 95% confidence interval [CI], 1.23-1.92; P<0.001) as well as higher serum alpha-fetoprotein (AFP, ≥400 ng/mL) and advanced tumor stage (modified Union for International Cancer Control [mUICC] IVb). Higher MRE-assessed LS was also significantly associated with the development of significant liver injury after sorafenib administration (kPa; HR, 1.62; 95% CI, 1.21-2.17; P=0.001). PFS analysis identified higher serum AFP (≥400 ng/mL) and advanced tumor stage (modified UICC IVb) as significant risk factors for early disease progression, whereas LS was not associated with PFS. Conclusions: Higher MRE-assessed LS is a potential biomarker for predicting poor OS and significant liver injury in advanced HCC patients treated with sorafenib.
Kim, Bohyun,Park, Seong Ho,Pickhardt, Perry J,Lee, Seung Soo,Ahn, Soyeon,Kim, Jihun,Kim, Jin Cheon,Yu, Chang Sik,Yang, Suk-Kyun,Kim, Ah Young,Ha, Hyun Kwon Radiological Society of North America 2014 Radiology Vol. No.
<P>To determine the postoperative incidence of adenomatous neoplasia in the colon proximal to an occlusive colorectal cancer where preoperative computed tomographic (CT) colonography findings were normal.</P>
Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer
Kim, Seo Ree,Shin, Kabsoo,Park, Jae Myung,Lee, Han Hong,Song, Kyo Yong,Lee, Sung Hak,Kim, Bohyun,Kim, Sang-Yeob,Seo, Junyoung,Kim, Jeong-Oh,Roh, Sang-Young,Kim, In-Ho The Korean Gastric Cancer Association 2020 Journal of gastric cancer Vol.20 No.4
Purpose: Isoform 2 of tight junction protein claudin-18 (CLDN18.2) is a potential target for gastric cancer treatment. A treatment targeting CLDN18.2 has shown promising results in gastric cancer. We investigated the clinical significance of CLDN18.2 and other cell-adherens junction molecules (Rho GTPase-activating protein [RhoGAP] and E-cadherin) in metastatic diffuse-type gastric cancer (mDGC). Materials and Methods: We evaluated CLDN18.2, RhoGAP, and E-cadherin expression using two-plex immunofluorescence and quantitative data analysis of H-scores of 77 consecutive mDGC patients who received first-line platinum-based chemotherapy between March 2015 and February 2017. Results: CLDN18.2 and E-cadherin expression was significantly lower in patients with peritoneal metastasis (PM) than those without PM at the time of diagnosis (P=0.010 and 0.013, respectively), whereas it was significantly higher in patients who never developed PM from diagnosis to death than in those who did (P=0.001 and 0.003, respectively). Meanwhile, CLDN18.2 and E-cadherin expression levels were significantly higher in patients with bone metastasis than in those without bone metastasis (P=0.010 and 0.001, respectively). Moreover, we identified a positive correlation between the expression of CLDN18.2 and E-cadherin (P<0.001), RhoGAP and CLDN18.2 (P=0.004), and RhoGAP and E-cadherin (P=0.001). Conversely, CLDN18.2, RhoGAP, and E-cadherin expression was not associated with chemotherapy response and survival. Conclusions: CLDN18.2 expression was reduced in patients with PM but significantly intact in those with bone metastasis. Furthermore, CLDN18.2 expression was positively correlated with other adherens junction molecules, which is clinically associated with mDGC and PM pathogenesis.
Kim Dong Hwan,Kim Bohyun,Choi Joon-Il,Oh Soon Nam,Rha Sung Eun 대한영상의학회 2022 대한영상의학회지 Vol.83 No.2
Purpose To systematically compare the performance of liver imaging reporting and data system treatment response (LR-TR) with the modified Response Evaluation Criteria in Solid Tumors (mRECIST) for diagnosing viable hepatocellular carcinoma (HCC) treated with locoregional therapy (LRT). Materials and Methods Original studies of intra-individual comparisons between the diagnostic performance of LR-TR and mRECIST using dynamic contrast-enhanced CT or MRI were searched in MEDLINE and EMBASE, up to August 25, 2021. The reference standard for tumor viability was surgical pathology. The meta-analytic pooled sensitivity and specificity of the viable category using each criterion were calculated using a bivariate random-effects model and compared using bivariate meta-regression. Results For five eligible studies (430 patients with 631 treated observations), the pooled per-lesion sensitivities and specificities were 58% (95% confidence interval [CI], 45%–70%) and 93% (95% CI, 88%–96%) for the LR-TR viable category and 56% (95% CI, 42%–69%) and 86% (95% CI, 72%–94%) for the mRECIST viable category, respectively. The LR-TR viable category provided significantly higher pooled specificity (p < 0.01) than the mRECIST but comparable pooled sensitivity (p = 0.53). Conclusion The LR-TR algorithm demonstrated better specificity than mRECIST, without a significant difference in sensitivity for the diagnosis of pathologically viable HCC after LRT.